<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T1" position="float">
 <label>TABLE 1</label>
 <caption>
  <p>Summary of protein- and peptide-based virus inactivators.</p>
 </caption>
 <table frame="hsides" rules="groups" cellspacing="5" cellpadding="5">
  <thead>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Name</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Sequence</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Target</td>
    <td valign="top" align="left" rowspan="1" colspan="1">EC50* (virus tested)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Reference</td>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td valign="top" align="left" colspan="5" rowspan="1">
     <bold>HIV inactivators</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">sCD4</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Extracellular D1–D4 or D1D2 domain</td>
    <td valign="top" align="left" rowspan="1" colspan="1">gp120 CD4bs</td>
    <td valign="top" align="left" rowspan="1" colspan="1">153 and 297 nM (HIV-1 IIIB and Bal, respectively)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B47" ref-type="bibr">Deen et al., 1988</xref>; 
     <xref rid="B144" ref-type="bibr">Traunecker et al., 1988</xref>; 
     <xref rid="B41" ref-type="bibr">Daar et al., 1990</xref>; 
     <xref rid="B111" ref-type="bibr">Orloff et al., 1993</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">2DLT</td>
    <td valign="top" align="left" rowspan="1" colspan="1">D1D2 domain-L35-T1144</td>
    <td valign="top" align="left" rowspan="1" colspan="1">gp120 CD4bs + gp41 PFI</td>
    <td valign="top" align="left" rowspan="1" colspan="1">17.3–78.6 nM (multiple HIV-1 strains)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B98" ref-type="bibr">Lu et al., 2012</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">2Dm2m/4Dm2m</td>
    <td valign="top" align="left" rowspan="1" colspan="1">2 or 4 mD1.22 with 2 m36.4</td>
    <td valign="top" align="left" rowspan="1" colspan="1">gp120 CD4bs + CoRbs</td>
    <td valign="top" align="left" rowspan="1" colspan="1">0.3–1.1 nM (HIV-1 IIIB)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B30" ref-type="bibr">Chen et al., 2014</xref>; 
     <xref rid="B123" ref-type="bibr">Qi et al., 2017</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Triazole KR13</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Modified peptide derived from 12p1 (RINNIPWSEAMM)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">gp120 CD4bs + CoRbs</td>
    <td valign="top" align="left" rowspan="1" colspan="1">0.5–25.6 μM (multiple HIV-1 strains)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B15" ref-type="bibr">Bastian et al., 2011</xref>, 
     <xref rid="B14" ref-type="bibr">2013</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">DAVEI</td>
    <td valign="top" align="left" rowspan="1" colspan="1">CVN + gp41 MPER</td>
    <td valign="top" align="left" rowspan="1" colspan="1">gp120 glycan sites + gp41</td>
    <td valign="top" align="left" rowspan="1" colspan="1">28.3 nM (HIV-1 Bal.01 pseudovirus)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B116" ref-type="bibr">Parajuli et al., 2018</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" colspan="5" rowspan="1">
     <bold>Influenza virus inactivators</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Urumin</td>
    <td valign="top" align="left" rowspan="1" colspan="1">IPLRGAFINGRWDSQCHRFSNGAIACA</td>
    <td valign="top" align="left" rowspan="1" colspan="1">H1 HA conserved stem</td>
    <td valign="top" align="left" rowspan="1" colspan="1">HNBD
     <sup>#</sup>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B75" ref-type="bibr">Holthausen et al., 2017</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" colspan="5" rowspan="1">
     <bold>ZIKV inactivators</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">DN59</td>
    <td valign="top" align="left" rowspan="1" colspan="1">E protein stem (aa 692–724): MAILDDTAWDFGSLGGVFTSIGKALHQ VFGAIY</td>
    <td valign="top" align="left" rowspan="1" colspan="1">DENV lipid membrane</td>
    <td valign="top" align="left" rowspan="1" colspan="1">4.8 μM (DENV-2)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B129" ref-type="bibr">Schmidt et al., 2010a</xref>, 
     <xref rid="B130" ref-type="bibr">b</xref>; 
     <xref rid="B97" ref-type="bibr">Lok et al., 2012</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Z2</td>
    <td valign="top" align="left" rowspan="1" colspan="1">E protein stem (aa 421–453): MAVLGDTAWDFGSVGGALNSLGKGIH QIFGAAF</td>
    <td valign="top" align="left" rowspan="1" colspan="1">ZIKV lipid membrane</td>
    <td valign="top" align="left" rowspan="1" colspan="1">2.52 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B159" ref-type="bibr">Yu et al., 2017</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" colspan="5" rowspan="1">
     <bold>HSV inactivators</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">gB94</td>
    <td valign="top" align="left" rowspan="1" colspan="1">gB ectodomain (aa 496–510): KTTSSIEFARLQFTY</td>
    <td valign="top" align="left" rowspan="1" colspan="1">HSV-1</td>
    <td valign="top" align="left" rowspan="1" colspan="1">125 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B1" ref-type="bibr">Akkarawongsa et al., 2009</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">gB122</td>
    <td valign="top" align="left" rowspan="1" colspan="1">gB ectodomain (aa 636–650): GHRRYFTFGGGYVYF</td>
    <td valign="top" align="left" rowspan="1" colspan="1">HSV-1 and 2</td>
    <td valign="top" align="left" rowspan="1" colspan="1">118 μM</td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B1" ref-type="bibr">Akkarawongsa et al., 2009</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">U-1</td>
    <td valign="top" align="left" rowspan="1" colspan="1">CRS on gB surface (aa 224–243): HRDDHETDMELKPANAATRT</td>
    <td valign="top" align="left" rowspan="1" colspan="1">HSV-1 and 2</td>
    <td valign="top" align="left" rowspan="1" colspan="1">HNBD
     <sup>#</sup>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B25" ref-type="bibr">Cetina-Corona et al., 2016</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">U-2</td>
    <td valign="top" align="left" rowspan="1" colspan="1">CRS on gB surface (aa 413–432): CIGKDARDAMDRIFARRYNA</td>
    <td valign="top" align="left" rowspan="1" colspan="1">HSV-1 and 2</td>
    <td valign="top" align="left" rowspan="1" colspan="1">HNBD
     <sup>#</sup>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B25" ref-type="bibr">Cetina-Corona et al., 2016</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">CB-1</td>
    <td valign="top" align="left" rowspan="1" colspan="1">CRS on gH surface (aa 609–626): QATRSETPVEVLAQQTHG</td>
    <td valign="top" align="left" rowspan="1" colspan="1">HSV-1 and 2</td>
    <td valign="top" align="left" rowspan="1" colspan="1">HNBD
     <sup>#</sup>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B25" ref-type="bibr">Cetina-Corona et al., 2016</xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">CB-2</td>
    <td valign="top" align="left" rowspan="1" colspan="1">CRS on gH surface (aa 646–664): PEASHRCGGQSANVEPRIL</td>
    <td valign="top" align="left" rowspan="1" colspan="1">HSV-1 and 2</td>
    <td valign="top" align="left" rowspan="1" colspan="1">HNBD
     <sup>#</sup>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <xref rid="B25" ref-type="bibr">Cetina-Corona et al., 2016</xref>)
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <attrib>
   <italic>*EC50, half maximal effective concentration causing virus inactivation. 
    <sup>#</sup>HNBD, has not been defined. CD4bs, CD4-binding site; CoRbs, coreceptor-binding site.
   </italic>
  </attrib>
 </table-wrap-foot>
</table-wrap>
